• Home
• Site Map
• Contact Us
• Graphics Version
• Printer Version

Main Navigation

• ABOUT US
  • COMPANY PROFILE
  • STRATEGY
  • MANAGEMENT TEAM
  • BOARD OF DIRECTORS
  • CONTACT US
• THERAPEUTIC FOCUS
  • CARDIOVASCULAR
  • CNS
    • Huntington's Disease
    • Myasthenia Gravis
    • Parkinson's Disease
    • Epilepsy
• PRODUCTS
  • PIPELINE
  • AMR101 for Hypertriglyceridemia
  • AMR101 for HD
  • EN101
  • SUBLINGUAL APOMORPHINE
  • NASAL LORAZEPAM
  • AMR103
• SCIENCE & TECHNOLOGY
  • INTRODUCTION
    • Lipophilic Platform
    • Targeted Lipid Transport Technology Platform
    • Cholinergic Platform
• PARTNERING
  • PARTNERING
  • BUSINESS DEVELOPMENT
  • STRATEGIC ALLIANCES
• INVESTOR RELATIONS
  • OVERVIEW
  • STOCK INFORMATION
  • CORPORATE GOVERNANCE
    • AUDIT COMMITTEE
    • REMUNERATION COMMITTEE
    • LEAD INDEPENDENT DIRECTOR
    • CODE OF ETHICS
    • MEMORANDUM AND ARTICLES OF ASSOCIATION
  • PRESENTATIONS
  • PRESS RELEASES
  • EVENTS
  • INVESTOR FAQ
  • REQUEST INVESTOR KIT
  • FINANCIAL REPORTS
  • SEC FILINGS
  • AGM 2008
  • EGM 2008
  • AGM 2007
  • ANALYST COVERAGE
  • EMAIL ALERTS
  • REQUEST INFORMATION